Grant: Master's Award: Canada Graduate Scholarships
McGill University
$27,000.00
Interactions between the amyloid precursor protein (APP) and glucose metabolism
EF 2024-25
Résumé
Alzheimer disease (AD) is the most common form of dementia, characterized by a decline in cognitive function and memory loss. There is currently no effective prevention or treatment of AD that restores cognitive function, thus making AD care an unmet clinical need. AD presents a threat to the amount of healthy years that a person will live. Therefore, it is imperative to understand the molecular basis of AD and develop disease-modifying medications. A key factor in AD development is mutations in the amyloid precursor protein (APP) which is causatively linked to AD. There is also found to be a continuous decrease in cerebral glucose uptake resembling what is seen in diabetes patients. Glucose enters the brain through the glucose transporter 1 (GLUT1) and it was found that AD patients express lower levels of it. This is likely contributing to the deficient uptake of glucose in these patients. Mice lacking APP were found to have significantly reduced levels of GLUT1, as well as AKT serine/threonine kinase 1 (AKT1) which is a regulator of GLUT1 expression. We will thus be investigating if certain growth factors are unable to properly induce AKT1 and GLUT1 expression in cells lacking APP. Furthermore, in order to determine which pathways are affected in cells lacking APP, compounds from the Library of Integrated Network-Based Cellular Signatures (LINCS) database that have been shown to revert the transcriptomic profile will be used. If one of these compounds is shown to be effective, the cell in which it was used will be sequenced before testing the compound in mice.Overall, a better understanding of APP's interaction and signaling network will lead to novel drug targets currently unexplored but that should have a high probability of being disease-modifying.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529626
Name
Savino Francesco
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Interactions between the amyloid precursor protein (APP) and glucose metabolism
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; App Signaling Network; Cognitive Decline; Glucose Metabolism; Glut1; Growth Factors; Molecular Biology; Novel Drug Targets; Pharmacological Interference; Rna Sequencing Analysis
Abstract
Alzheimer disease (AD) is the most common form of dementia, characterized by a decline in cognitive function and memory loss. There is currently no effective prevention or treatment of AD that restores cognitive function, thus making AD care an unmet clinical need. AD presents a threat to the amount of healthy years that a person will live. Therefore, it is imperative to understand the molecular basis of AD and develop disease-modifying medications. A key factor in AD development is mutations in the amyloid precursor protein (APP) which is causatively linked to AD. There is also found to be a continuous decrease in cerebral glucose uptake resembling what is seen in diabetes patients. Glucose enters the brain through the glucose transporter 1 (GLUT1) and it was found that AD patients express lower levels of it. This is likely contributing to the deficient uptake of glucose in these patients. Mice lacking APP were found to have significantly reduced levels of GLUT1, as well as AKT serine/threonine kinase 1 (AKT1) which is a regulator of GLUT1 expression. We will thus be investigating if certain growth factors are unable to properly induce AKT1 and GLUT1 expression in cells lacking APP. Furthermore, in order to determine which pathways are affected in cells lacking APP, compounds from the Library of Integrated Network-Based Cellular Signatures (LINCS) database that have been shown to revert the transcriptomic profile will be used. If one of these compounds is shown to be effective, the cell in which it was used will be sequenced before testing the compound in mice.Overall, a better understanding of APP's interaction and signaling network will lead to novel drug targets currently unexplored but that should have a high probability of being disease-modifying.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Savino, Francesco
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~